Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Idaho: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 389 | 37% |
| 2020 | 2 | 342 | 40% |
| 2021 | 2 | 379 | 43% |
| 2022 | 3 | 371 | 47% |
| 2023 | 6 | 383 | 50% |
| 2024 | 5 | 440 | 52% |
| 2025 from claims | – | 457 369–536 | 54% |
| 2026 forecast | – | 534 418–670 | 49% |
| 2027 forecast | – | 569 422–752 | 49% |
| 2028 forecast | – | 606 429–837 | 49% |
| 2029 forecast | – | 646 439–927 | 49% |
| 2030 forecast | – | 689 451–1,022 | 48% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Idaho; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 91% hospital outpatient, 4% surgery center, 5% office. The share outside the hospital has moved +4 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 85 | 6,904+1.6%/yr | +1.6%/yr | 2.3 | 25% | 7,960 in 2030+2.4%/yr |
| Arizona | 21 | 1,973+0.3%/yr | +0.3%/yr | 2.9 | 22% | 2,360 in 2030+3%/yr |
| Washington | 21 | 1,715−1.7%/yr | −1.7%/yr | 2.4 | 4% | 2,300 in 2030+5%/yr |
| Colorado | 11 | 1,230+1.8%/yr | +1.8%/yr | 2.8 | 8% | 1,580 in 2030+4.2%/yr |
| Oregon | 10 | 1,031+0.7%/yr | +0.7%/yr | 2.7 | 14% | 1,100 in 2030+1.1%/yr |
| Nevada | 3 | 560−0.8%/yr | −0.8%/yr | 2.1 | 20% | 610 in 2030+1.5%/yr |
| New Mexico | 5 | 427−0.8%/yr | −0.8%/yr | 2.0 | 16% | 400 in 2030−1.2%/yr |
| Montana | 7 | 426+5.8%/yr | +5.8%/yr | 2.4 | 8% | 720 in 2030+9.1%/yr |
| Utah | 2 | 384−2.1%/yr | −2.1%/yr | 1.9 | 11% | 380 in 2030−0.1%/yr |
| Alaska | 2 | 275+7.4%/yr | +7.4%/yr | 2.3 | 26% | 220 in 2030−3.5%/yr |
| Hawaii | 2 | 214+5.1%/yr | +5.1%/yr | 1.9 | 14% | 220 in 2030+0.1%/yr |
| Wyoming | 0 | 120+2.1%/yr | +2.1%/yr | 1.1 | 20% | 140 in 2030+2.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 17 | 1,020−1.6%/yr | −1.6%/yr | 5.01.1× | 38% | 1,180 in 2030+2.4%/yr |
| Kidney stone management | 20 | 895−1%/yr | −1%/yr | 4.41.2× | 21% | 1,470 in 2030+8.6%/yr |
| Incontinence, prolapse & sacral neuromodulation | 4 | 408+1.3%/yr | +1.3%/yr | 2.01.1× | 11% | 900 in 2030+14%/yr |
| Prostatectomy & nephrectomy | 5 | 276+4.7%/yr | +4.7%/yr | 1.51.2× | 0% | 260 in 2030−1.1%/yr |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Idaho · Every state · Compare with California
Hologic Sales And Service leads with 100% of company spending on these surgeons in 2025, +20 pts on 2024.
In 2025, 1 company reported engagement with Idaho’s surgeons worth $2,777 in consulting, speaking, meals and travel tied to these products, about $555 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.